A major development made by the Board of Radiation and Isotope Technology (BRIT) has successfully developed Thallous Chloride radiopharmaceutical. This is an exceptional breakthrough in the field of radiopharmaceuticals development, thanks to 30 MeV medical cyclotron facility operated by Variable Energy Cyclotron Centre (VECC), Kolkata. It will help reduce the import of the Thallium-201 radioisotope in the future and aid widespread availability at an affordable cost.
A radiopharmaceutical is a molecule that is designed where at least one of the atoms (called radioisotope) in the molecule is radioactive. It is this atom that emits radiation (gamma or beta) then detected by detectors. In final analysis shows the functioning of the target organ.
Thallium-201 is a gamma-emitting radioisotope used in a certain diagnostic application called Single Photon Emission Computed Tomography (SPECT). SPECT is a collection of detectors that senses the radiation coming out of the body.
Thallous chloride is supplied to Rabindra Tagore International Institute of Cardiac Studies for viability studies and assessment in patients referred to suspected coronary artery diseases evaluation and recorded remarkable results. Thallium-201 showed good biological distributions and better cardiac uptake which results in better image quality. In India, the radioisotope is used in wide industrial applications but has been used for human applications for the first time. For the first time in India, the indigenously produced Tl-201 radioisotope has been used for human applications.